K

Eli Lilly & Company logo

Eli Lilly & Company

Crunchbase
Crunchbase

Deals on record

17

Common Fundraising Type

Series B

Augustine Therapeutics logo
Augustine Therapeutics

Biotechnology • Therapies

VIB logo
V-Bio Ventures logo
PMV logo
Novo Holdings logo

Augustine Therapeutics is a biotechnology company developing therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases through selective inhibition of the HDAC6 enzyme.

Series A
$84.2M
03/24/2025
Article
Ampersand Biomedicines logo
Ampersand Biomedicines

Immuno-inflammation • Immuno-oncology

Flagship Pioneering logo
Eli Lilly & Company logo

Ampersand Biomedicines develops smart medicines using their AND™ platform to precisely target specific areas in the body for improved therapeutic effects in immuno-inflammation and immuno-oncology.

Series B
$65M
03/19/2025
Article
TRIMTECH Therapeutics logo
TRIMTECH Therapeutics

Biotech • Targeted protein degradation

SV Health Investors logo
Cambridge Innovation Capital logo
Pfizer Ventures logo
MP Healthcare Venture Management logo

TRIMTECH Therapeutics is a biotech company developing targeted protein degradation therapeutics for neurodegenerative diseases using TRIMTAC degrader molecules.

Seed
$32M
03/05/2025
Article
Orbis Medicines logo
Orbis Medicines

Oral macrocycle drugs • NCycles

NEA logo
Novo Holdings logo
Forbion logo
Export and Investment Fund of Denmark logo

Orbis Medicines develops oral macrocycle drugs as alternatives to biologic drugs using their nGen platform, which combines automated chemistry and machine learning.

Series A
$92.7M
01/06/2025
Article
Revisto logo
Revisto

Pharmaceutical • Marketing

LiveOak Ventures logo
Tau Ventures logo
Eli Lilly and Company logo
Arkin Digital Health logo

Revisto uses AI-driven automation to streamline and enhance pharmaceutical marketing compliance by optimizing the medical, legal, and regulatory review process.

Seed
$4M
11/18/2024
Article
TRexBio logo
TRexBio

Biotechnology • Inflammatory Diseases

Delos Capital logo
Avego BioScience Capital logo
SV Health Investors logo
Pfizer Ventures logo

TRexBio is a biotechnology company developing novel therapies for inflammatory diseases using their Deep Biology platform to focus on immune homeostasis.

Series B
$84M
11/13/2024
Article
Sunbird Bio logo
Sunbird Bio

Biotechnology • Blood-based diagnostics

Polaris Partners logo
S32 logo
Eli Lilly and Company logo
EDBI logo

Sunbird Bio develops a blood-based diagnostic platform for early and accurate detection of neurological disorders like Alzheimer’s and Parkinson’s disease.

Equity
$14M
10/16/2024
Article
Arda Therapeutics logo
Arda Therapeutics

Targeted cell depletion • Chronic diseases

Andreessen Horowitz logo
Two Sigma Ventures logo
RV Invest logo
Eli Lilly and Company logo

Arda Therapeutics develops targeted cell depletion therapies for chronic diseases.

Series A
$43M
10/09/2024
Article
Aktis Oncology logo
Aktis Oncology

Biotechnology • Clinical-stage

RA Capital Management logo
RTW Investments logo
Janus Henderson Investors logo
T. Rowe Price Associates logo

Aktis Oncology is a clinical-stage biotechnology company developing a proprietary radiopharmaceutical pipeline, including Nectin-4-targeted miniprotein radioconjugates, for cancer treatment.

Series B
$175M
09/30/2024
Article
NanoSyrinx logo
NanoSyrinx

Synthetic biotech • Nano syringe

BGF logo
Octopus Ventures logo
Meltwind logo
M Ventures logo

NanoSyrinx is a synthetic biotech company developing a nano syringe delivery platform for intracellular delivery of biologic therapeutics.

Equity
$13.1M
09/10/2024
Article
OrsoBio logo
OrsoBio

Biopharmaceutical • Clinical-stage

Ascenta Capital logo
Woodline Partners logo
Samsara Biocapital logo
NuevaBio logo

OrsoBio, Inc. is a clinical-stage biopharmaceutical company developing novel mitochondrial protonophore therapies targeting obesity and associated metabolic disorders.

Series B
$67M
09/06/2024
Article
Alto Neuroscience logo
Alto Neuroscience

Precision Psychiatry • Brain Biomarkers

InVivium Capital logo
Windham Venture Partners logo
WhatIf Ventures logo
Point72 logo

Alto Neuroscience specializes in precision psychiatry, developing targeted medicines based on its Precision Psychiatry Platform™, which utilizes brain biomarkers to match patients with appropriate treatments.

Series C
$45M
11/21/2023
Article
ViaNautis logo
ViaNautis

Nanomedicine • Polymer Technology

UCB Ventures logo
Origin Capital logo
O2H logo
Meltwind logo

ViaNautis Bio specializes in nano-engineered polymer technology, PolyNaut®, which enables targeted intracellular delivery of therapeutic payloads.

Series A
$25M
11/13/2023
Article
OrsoBio logo
OrsoBio

Biopharmaceutical • Clinical-stage

Samsara BioCapital logo
Longitude Capital logo
Enavate Sciences logo
NuevaBio logo

OrsoBio, Inc. is a clinical-stage biopharmaceutical company developing novel mitochondrial protonophore therapies targeting obesity and associated metabolic disorders.

Series A
$60M
11/07/2023
Article
Laverock Therapeutics logo
Laverock Therapeutics

Gene Therapy • Regenerative Medicine

UK Innovation & Science Seed Fund logo
Tekfen Ventures logo
Mercia Ventures logo
Maven Capital Partners logo

Laverock Therapeutics is a UK-based biotech company that develops a gene silencing platform for advanced human therapeutic applications, with a focus on regenerative medicine and immuno-oncology.

Seed
$16.4M
09/28/2023
Article
Sitryx Therapeutics logo
Sitryx Therapeutics

Biopharmaceutical • Immunometabolism

GSK logo
SV Health Investors logo
Sofinnova Partners logo
Oxford Science Enterprises logo

Sitryx Therapeutics is a biopharmaceutical company that develops disease-modifying therapeutics for chronic autoimmune and inflammatory diseases by targeting and regulating cell metabolism.

Equity
$39M
09/27/2023
Article
Mariana Oncology logo
Mariana Oncology

Biotechnology • Oncology

Forbion logo
Deep Track Capital logo
Surveyor Capital logo
RA Capital Management logo

Mariana Oncology is a biotechnology company that develops targeted peptide-based radiopharmaceuticals for the treatment of cancer, with a focus on delivering optimized radiation doses to solid tumors.

Series B
$175M
09/07/2023
Article